Crescen­do snares $70M Se­ries B for its tu­mor-fight­ing tech

A tiny com­pa­ny in Cam­bridge, UK has hauled in one of the biggest Eu­ro­pean fi­nanc­ing rounds of the year — $70 mil­lion in a Se­ries B round — to push for­ward its on­col­o­gy pipeline.

The biotech, called Crescen­do Bi­o­log­ics, has a plat­form tech that’s the ba­sis for a num­ber of pre­clin­i­cal pro­grams, in­clud­ing its lead drug CB307, which boosts an an­ti-tu­mor im­mune re­sponse right in the tu­mor mi­croen­vi­ron­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.